Cybin Corp. Announces Reverse Take-Over Transaction and the Engagement of Stifel GMP and Eight Capital to Co-Lead ConcurHAVN Life Sciences Continues To Execute On Growth Initiatives Ahead Of Its Upcoming Public ListingMindMed Developing IP For Personalized Psychedelic Assisted TherapiesNuminus announces Clinical Advisory Council to advance integrated wellness modelRritual Announces Dr. Mike Hart as PresidentThe Multi-Billion Dollar Functional Mushroom Market Is Up For GrabsMydecine Innovations Group Bolsters Scientific Advisory Board Adding a Leading Neuroscientist and a Psychopharmacology SField Trip Is Shifting Gears To Expedite IPO ProcessMydecine Innovations Group Signs Definitive Agreement to Acquire Mindleap Health’s Advanced Digital Telehealth PlatforNew Wave Holdings Corp Appoints Dr. Carolyn Myers As VP Of Commerical DevelopmentNew Wave Holdings Corp Appoints Dr. Dennis McKenna to Psychedelic Research Advisory BoardChampignon Provides Corporate Update; Announces Name Change, Rebranding and Planned Spin OutRed Light Holland Announces Closing of Second Tranche of Private PlacementNuminus Wellness Has Big Plans To Scale Operations In The Back Half of 2020 Following A Major License Amendment By HealtMydecine Innovations Group Inc. Signs Partnership Agreement With Applied Pharmaceutical InnovationCybin Corp: A Mushroom Life Sciences Leader In The MakingChampignon Announces Closing of $15 Million Bought Deal Private PlacementNuminus receives Health Canada licence amendment to produce and extract psilocybin from mushroomsPharmaDrug Receives Conditional Approval for Grant of OptionsWake Network Is Creating A Multi-Faceted Platform To Bring Psychedelic Therapies To Market
Back

MindMed Inks Deal With Switzerland University For Rights On LSD Research

Apr 7, 2020 • 1:04 PM EDT
1 MIN READ  •  By Anthony Varrell
Share Share - Facebook Share - Twitter

Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NEO: MMED) (OTC: MMEDF) has acquired exclusive rights to data, compounds, and patents for research with LSD and other psychedelics from the Liechti laboratory in Switzerland’s University Hospital Basel.

Exploring High-Dose LSD Treatment for Anxiety

MindMed CEO JR Rahn told Benzinga that much emphasis has been placed on psilocybin in recent years as a psychedelic therapy model, but the potential safety and efficacy of LSD in hallucinogenic psychotherapy may provide an even greater promise for patients.

“Over the past decade we have amassed the largest collection of clinical trials around LSD,” said Matthias Liechti, who heads the psychedelics research lab at University Hospital Basel. “We have been studying the pharmacology and potential medical uses of LSD and other psychedelics for many years in the laboratory, in patients, and in healthy volunteers.”

MindMed has special interest in an Phase 2 trial on high-dose LSD treatment for anxiety currently being conducted by Liechti’s lab. The company will also work under the direction of Liechti to continue developing therapy with LSD micro-dose as potential treatment for adult ADHD.

MindMed hopes to leverage the impactful data and clinical trials Liecthi and his team have “diligently executed on in LSD for 10 plus years,” the company said.

Through future commercial clinical drug trials, the goal is to turn LSD into an FDA approved medicine as a way to treat mental illnesses.

Share Share - Facebook Share - Twitter

Tags

Authored By

Anthony Varrell

Anthony Varrell is Managing Director of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link